Propericiazine and its active metabolite periciazine are not approved for marketing in the United States by the U.S. Food and Drug Administration, but are available in other countries. Minimal information from one patient indicates that the amount of periciazine is low in milk after administration of propericiazine. If propericiazine or periciazine is required by the mother, it is not a reason to discontinue breastfeeding, but until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
丙嗪及其活性代谢产物奋乃静未被美国食品药品监督管理局批准在美国上市，但在其他国家有销售。来自一名患者的极少信息表明，服用丙嗪后母乳中奋乃静的含量较低。如果母亲需要使用丙嗪或奋乃静，这并非停止母乳喂养的理由，但在获得更多数据之前，可能更倾向于选择替代药物，尤其是在哺育新生儿或早产儿期间。
